Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / France

European Research Council grant · Running

MENTOR Maintenance of platelet homeostasis by tyrosine phosphatases and vascular heparan sulfates

Coordinator
Institut National De La Sante Et De La Recherche Medicale, France
Runs
1 September 2025 to 31 August 2030
Status
Running
EU funding
€2.5m
Total cost
€2.5m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101141783

What the project is doing

In the project's own words, from its summary on CORDIS.

Platelets are highly reactive fragments of megakaryocytes (MKs) that have been implicated in all major pathophysiological processes, but the molecular mechanisms controlling the number and reactivity of platelets in the circulation remain incompletely defined. The prevailing thinking is that mechanical forces are the primary drivers of platelet production, but the logic is flawed and the evidence contradictory. What is glaringly overlooked are intrinsic inhibitory mechanisms and extrinsic cues providing a break system and directionality to MKs.

Central to this model is the concept of an MK/platelet checkpoint and gatekeeper preventing platelet production in a haphazard manner, which has never been applied to this fundamental physiological process. Based on pioneering work from my laboratory, I hypothesize that protein-tyrosine phosphatase (PTP)-linked receptors and vascular heparan sulfates (HS) are critical regulators of platelet production, and that these receptors can be harnessed through the use of synthetic heterobifunctional molecules to regulate the threshold of MK/platelet activation and function in health and disease.

Critical components of this mechanism, include the co-inhibitory receptor G6B that signals via the non-transmembrane PTPs Shp1 and Shp2, is regulated by vascular HSs, and is the primary gatekeeper of the MK/platelet checkpoint; and the receptor-type PTP CD148 that is regulated by vascular HS proteoglycans and extracellular matrix proteins, and is a master regulator of Src family kinases and the threshold of MK/platelet activation.

Findings from this proposal will revolutionize MK/platelet biology and pioneer a novel class of tools and therapeutics for investigating and treating MK/platelet-based pathologies.

Topics

Who is involved

OrganisationCityCountryRole
Institut National De La Sante Et De La Recherche MedicaleParisFranceCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI